New-generation antibiotics for treatment of gram-positive infections: A review with focus on endocarditis and osteomyelitis

Annemieke Bloem*, Hannelore I. Bax, Erlangga Yusuf, Nelianne J. Verkaik

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)
2 Downloads (Pure)

Abstract

Infective endocarditis, osteomyelitis, and osteosynthesis-associated infections are mostly caused by Gram-positive bacteria. They are often difficult to treat and are associated with a poor prognosis. In the past 20 years, nine antibiotic drugs with predominant activity against Gram-positive bacteria have been introduced and approved by the Food and Drug Administration or the European Medicines Agency: ceftaroline, daptomycin, telavancin, dalbavancin, oritavancin, linezolid, tedizolid, delafloxacin, and omadacycline. This narrative review aims to provide an overview on these antibiotics with a special focus on their use in infective endocarditis, osteomyelitis, and osteosynthesis-associated infections. Although some of these approved antibiotics are promising, they should not be used as first-or second-line therapy, awaiting more clinical data.

Original languageEnglish
Article number1743
JournalJournal of Clinical Medicine
Volume10
Issue number8
DOIs
Publication statusPublished - 17 Apr 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Fingerprint

Dive into the research topics of 'New-generation antibiotics for treatment of gram-positive infections: A review with focus on endocarditis and osteomyelitis'. Together they form a unique fingerprint.

Cite this